2Sarosdy MF, Schellhammer PF, Sharifi R, et al. Comparison of guserelin and Leuprolide in Combined androgen blockage therapy[J]. Urology, 1998, 52(1): 82-88.
3Prostate Cancer trialists Collaborative Group. Maximum androgen blockade in advanced Prostate Cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients [J]. Lancet,1995, 346(8970): 265-269.
4Labrie F, Dupont A, Giguere M, et al. Advantages of Combinaion therapy in prebiously Untreated and treated patients with advanced Prostatic Cancer [J]. J Steroid Biochem, 1986, 25 (SB):877-883.
5Garnick MB. Prostate Cancer: screening, diagnosis and man agement[]]. Ann Intern Med, 1993, 118(10): 804-818.
4Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer [J]. Prostate, 1998, 35(4): 285-296.
5CosteUo LC,Franklin RB.The intermediary metabofism of the prostate:a key to understanding the pathogenesis and progression of prostate malignancy[J].Oncology, 2000, 59(4): 269-282.
6KurhanewiczJ, Vigneron DB, Hricak H,et al. Prostate cancer:metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging[J]. Radiology,1996,200(2): 489-496.
7Zaichick VYe, Sviridova TV, Zalchick SV. Zinc in the human prostate grand: normal, hyperplastic and cancerous[J]. Int Urol Nephrol, 1997, 29(5): 565-574.
8Cortesi M, Fridman E, Volkov A, et al. Clinical assessment of the cancer diagnostic value of prostatic zinc: a comprehensive needie-biopsy study[J]. Prostate, 2008, 68(9): 994-1006.
9Wong YC, Wang YZ, LeeJS, et al. Changes in serum and tissue zinc leveLs in sex hormone- induced prostatic carcinogenesis in the noble rat[J]. Tumour Biol, 2000, 21(6): 328-336.
10Vartsky D, Shilstein S, Bercovich A, et al. Prostatic zinc and prostate specific antigen: an experimental evaluation of their combined diagnostic value[J].J Urol, 2003, 170(6 Pt1): 2258-2262.
